The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Inaqovi cedazuridine;decitabine Additional monitoring | Otsuka Pharmaceutical Netherlands B.V. | Leukemia, Myeloid | 🇪🇺 EU 2023-09-15 | Order → |
| Litfulo ritlecitinib Additional monitoring | Pfizer Europe MA EEIG | Alopecia Areata | 🇪🇺 EU 2023-09-15 | Order → |
| Lyfnua gefapixant Additional monitoring | Merck Sharp & Dohme B.V. | Cough | 🇪🇺 EU 2023-09-15 | Order → |
| Orserdu elacestrant Additional monitoring | Stemline Therapeutics B.V. | Breast Neoplasms | 🇪🇺 EU 2023-09-15 | Order → |
| Tevimbra tislelizumab Additional monitoring | Beone Medicines Ireland Limited | Esophageal Squamous Cell Carcinoma; Carcinoma, Non-Small-Cell Lung; Small Cell Lung Carcinoma; Nasopharyngeal Carcinoma; Stomach Neoplasms | 🇪🇺 EU 2023-09-15 | Order → |
| Tyenne tocilizumab Biosimilar | Fresenius Kabi Deutschland GmbH | Arthritis, Rheumatoid; Cytokine Release Syndrome; Arthritis, Juvenile Rheumatoid; COVID-19 virus infection; Giant Cell Arteritis | 🇪🇺 EU 2023-09-15 | Order → |
| Yesafili aflibercept BiosimilarAdditional monitoring | Biosimilar Collaborations Ireland Limited | Macular Edema; Retinal Vein Occlusion; Diabetic Retinopathy; Myopia, Degenerative; Diabetes Complications | 🇪🇺 EU 2023-09-15 | Order → |
| Abrysvo respiratory syncytial virus vaccine (bivalent, recombinant) Accelerated assessmentAdditional monitoring | Pfizer Europe MA EEIG | Respiratory Syncytial Virus Infections | 🇪🇺 EU 2023-08-23 | Order → |
| Talvey talquetamab PRIMEConditionalAdditional monitoring | Janssen-Cilag International N.V. | Multiple Myeloma | 🇪🇺 EU 2023-08-21 | Order → |
| Aquipta atogepant Additional monitoring | AbbVie Deutschland GmbH & Co. KG | Migraine Disorders | 🇪🇺 EU 2023-08-11 | Order → |
| Ztalmy ganaxolone OrphanAdditional monitoring | Marinus Pharmaceuticals Emerald Limited | Epileptic Syndromes; Spasms, Infantile | 🇪🇺 EU 2023-07-26 | Order → |
| Columvi glofitamab Additional monitoring | Roche Registration GmbH | Lymphoma, Large B-Cell, Diffuse | 🇪🇺 EU 2023-07-07 | Order → |
| Lytgobi futibatinib ConditionalAdditional monitoring | Taiho Pharma Netherlands B.V. | Cholangiocarcinoma | 🇪🇺 EU 2023-07-04 | Order → |
| Camzyos mavacamten Additional monitoring | Bristol-Myers Squibb Pharma EEIG | Cardiomyopathy, Hypertrophic | 🇪🇺 EU 2023-06-26 | Order → |
| Opfolda miglustat | Amicus Therapeutics Europe Limited | Glycogen Storage Disease Type II | 🇪🇺 EU 2023-06-26 | Order → |
| Sugammadex Piramal sugammadex Generic | Piramal Critical Care B.V. | Neuromuscular Blockade | 🇪🇺 EU 2023-06-23 | Order → |
| Arexvy Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted) | GlaxoSmithKline Biologicals S.A. | Respiratory Syncytial Virus Infections | 🇪🇺 EU 2023-06-06 | Order → |
| Briumvi ublituximab Additional monitoring | Neuraxpharm Pharmaceuticals S.L. | Multiple Sclerosis, Relapsing-Remitting; Multiple Sclerosis | 🇪🇺 EU 2023-05-31 | Order → |
| Lacosamide Adroiq lacosamide Generic | Extrovis EU Ltd | Epilepsy | 🇪🇺 EU 2023-05-31 | Order → |
| Dabigatran Etexilate Accord dabigatran etexilate Generic | Accord Healthcare S.L.U. | Venous Thromboembolism; Arthroplasty, Replacement | 🇪🇺 EU 2023-05-26 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.